Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension
Acta Pharmaceutica Sinica B · 2024-04 · 14 (4) · 1726-1741
DOI: 10.1016/j.apsb.2024.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-04. Verfasst von Yanjiang Xing und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pulmonary hypertension (PH) is a fatal disorder characterized by pulmonary vascular remodeling and obstruction. The phosphodiesterase 4 (PDE4) family hydrolyzes cyclic AMP (cAMP) and is comprised of four subtypes (PDE4A-D). Previous studies have shown the beneficial effects of pan-PDE4 inhibitors in rodent PH; however, this class of drugs is associated with side effects owing to the broad inhibition of all four PDE4 isozymes. Here, we demonstrate that PDE4B is the predominant PDE isozyme in lungs and that it was upregulated in rodent and human PH lung tissues. We also confirmed that PDE4B is mainly expressed in the lung endothelial cells (ECs). Evaluation of PH in Pde4b wild type and knockout mice confirmed that Pde4b is important for the vascular remodeling associated with PH. In vivo EC lineage tracing demonstrated that Pde4b induces PH development by driving endothelial-to-mesenchymal transition (EndMT), and mechanistic studies showed that Pde4b regulates EndMT by antagonizing the cAMP-dependent PKA-CREB-BMPRII axis. Finally, treating PH rats with a PDE4B-specific inhibitor validated that PDE4B inhibition has a significant pharmacological effect in the alleviation of PH. Collectively, our findings indicate a critical role for PDE4B in EndMT and PH, prompting further studies of PDE4B-specific inhibitors as a therapeutic strategy for PH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, China.
- Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300051, China.
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610044, China.
- Department of Lung Transplantation, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Institute of Respiratory Medicine, Chinese Acade…
- The State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing 100005, Chin…
Zitieren
APA
Xing, Y., Hou, Y., Fan, T., Gao, R., Feng, X., Li, B., Pang, J., Guo, W., Shu, T., Li, J., Yang, J., Mao, Q., Luo, Y., Qi, X., Yang, P., Liang, C., Zhao, H., Chen, W., Wang, J., & Wang, C. (2024). Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension. Acta Pharmaceutica Sinica B, 14(4), 1726-1741. https://doi.org/10.1016/j.apsb.2024.01.012
Vancouver
Xing Y, Hou Y, Fan T, Gao R, Feng X, Li B, et al. Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension. Acta Pharmaceutica Sinica B. 2024;14(4):1726-1741. doi:10.1016/j.apsb.2024.01.012
BibTeX
@article{Xing2024,
author = {Xing, Yanjiang and Hou, Yangfeng and Fan, Tianfei and Gao, Ran and Feng, Xiaohang and Li, Bolun and Pang, Junling and Guo, Wenjun and Shu, Ting and Li, Jinqiu and Yang, Jie and Mao, Qilong and Luo, Ya and Qi, Xianmei and Yang, Peiran and Liang, Chaoyang and Zhao, Hongmei and Chen, Wenhui and Wang, Jing and Wang, Chen},
title = {Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension},
journal = {Acta Pharmaceutica Sinica B},
year = {2024},
volume = {14},
number = {4},
pages = {1726--1741},
doi = {10.1016/j.apsb.2024.01.012}
}
EUVIMED